Janux Therapeutics Inc’s filing revealed that its FORMER OFFICER Reardon Tighe acquired Company’s shares for reported $0.28 million on Nov 01 ’24. In the deal valued at $53.44 per share,5,202 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Lichter Jay bought 1,139 shares, generating $60,723 in total proceeds.
Before that, Avalon Ventures XI, L.P. bought 56,440 shares. Janux Therapeutics Inc shares valued at $3,028,665 were divested by the 10% Owner at a price of $53.66 per share.
UBS initiated its Janux Therapeutics Inc [JANX] rating to a Buy in a research note published on October 24, 2024; the price target was $69. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Scotiabank began covering JANX with “Sector perform” recommendation on May 30, 2024. BTIG Research started covering the stock on March 21, 2024. It rated JANX as “a Buy”.
Price Performance Review of JANX
On Friday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -4.58% to $48.76. Over the last five days, the stock has lost -9.57%. Janux Therapeutics Inc shares have risen nearly 354.43% since the year began. Nevertheless, the stocks have risen 455.35% over the past one year. While a 52-week high of $65.60 was reached on 05/03/24, a 52-week low of $7.79 was recorded on 02/05/24. SMA at 50 days reached $49.76, while 200 days put it at $42.91.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 47.70, which if violated will result in even more drops to 46.65. On the upside, there is a resistance level at 50.45. A further resistance level may holdings at 52.15. The Relative Strength Index (RSI) on the 14-day chart is 38.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.68%. Stochastics %K at 10.58% indicates the stock is a buying.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2024-10-31, growing by 0.85 million shares to a total of 4.31 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.46 million shares. There was a rise of 19.72%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 20, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $100 price target.
